Unity Biotechnology, Inc. (UBX)

$ 1.89
-0.04 (-2.07%)
Symbol UBX
Price $ 1.89
Beta 0.117
Volume Avg. 0.80M
Market Cap 0.109B
Shares () -
52 Week Range 1.8162-9.78
1y Target Est -
DCF Unlevered UBX DCF ->
DCF Levered UBX LDCF ->
ROE -69.99% Strong Sell
ROA -39.88% Strong Sell
Operating Margin -
Debt / Equity 117.70% Buy
P/E -
P/B 1.81 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest UBX news

Dr. Anirvan Ghosh
Nasdaq Global Select

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.